The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
Figure 1
Treatment with PPAR agonists, gemfibrozil and rosiglitazone reduces glomerulosclerosis (a) and tubulointerstitial expansion (b) in streptozotocin diabetic apolipoprotein E knockout mice [25]. Data shows mean ± SEM; *versus control , #versus diabetes ).
